期刊文献+

环孢素A纳米乳输液剂的制备及含量测定 被引量:4

Preparation and Content Determination of Cyclosporine A Nano-emulsion
下载PDF
导出
摘要 目的:制备环孢素纳米乳输液剂并采用HPLC法测定该纳米乳制剂中环孢素A的含量。方法:以注射用大豆油为油相,磷脂为乳化剂,采用高压均制法制备环孢素纳米乳。HPLC法测定含量,采用Hypersil C18(ODS2)色谱柱(4.6mm×250mm,5岬);流动相为甲醇:水(85:15,V:V);流速为1mL/min;检测波长为225nm;柱温为50℃。结果:所制纳米乳平均粒径为35.9nm,表面电位为-33.1mV。可耐热压灭菌。在本实验分离条件下环孢素A与其他组分能较好地分离,环孢素A浓度在20—300mg/L范围内呈线形关系(r=0.9999),在高、中、低3个浓度的回收率(n=3)分别为100.28%(RSD=0.76%),100.91%(RSD=0.65%),101.11%(RSD=0.86%)。结论:制备的纳米乳稳定性较好,测定方法可以用于环孢素A纳米乳的含量测定。 Objective:To prepare Cyclosporine A(CsA) nano-emulsion injection and to determine the content of cyclosporine A(CsA) in the nano-emulsion by HPLC. Methods:An injectable soybean oil was used as the oil phase and lipoid S75 was used as the emulsifying agent. The CsA nano-emulsion injection was prepared by high pressure homogeniziton method. To determine the content, A Hypersil ODS2 (4.6 mm ×250 mm, 5 μm)with the column temperature of 50 ℃ was used. And the orther conditions under HPLC were as follows: mobile phase of methanol-water (85: 15), the flow rate of 1mL/min and the UV detector wavelength of 225 nm. Results: The average diameter of the prepared nano-emulsion was 35.9 nm with the zeta potential of - 33.1 mV. The nano-emulsion could endure the high pressure steam sterilization. Under these test conditions of HPLC, CsA could be isolated from other components. The calibration curves were liner in the range of 20 - 300 μg/mL ( r = 0.999 9) for CsA. The recovery rates of three different concentrations were 100.28 % ( RSD = 0.79 % ), 100.91% ( RSD = 0.65 % ), 101.11% ( RSD = 0.86% ) respectively. Conclusion: The nano-emulsion was stable and the HPLC method could be used for determining the content of CsA in the nano-emulsion injection.
出处 《药学进展》 CAS 2008年第4期173-176,共4页 Progress in Pharmaceutical Sciences
关键词 纳米乳 环孢素A 制备 含量测定 Nano-emulsion Cyclosporine A Perparation Content determination
  • 相关文献

参考文献3

  • 1Chan F K L, Shaffer E A. Cholestasis effects of cyclosporine in the rat [J]. Transplantation, 1997, 63 ( 11 ) : 1574-1578.
  • 2Cordes N, Plasswilm L. Cell line and schedule-dependent eytotoxieity of Toxol: role of the solvent Cremophor EL [J]. AnticancerRes, 1998,18 (3A):1851-1857.
  • 3Fernandez P, Andr' e V, Rieger J, et al. Nano-emulsion formation by emulsion phase inversion [J]. Colloids Surf A: Physicochem Eng Asp, 2004, 251 : 53-58.

同被引文献1975

  • 1奉建芳.我国纳米给药系统的研究与应用[J].中南药学,2004,2(1):29-33. 被引量:14
  • 2王彦,张燕.二阶导数光谱法测定硫酸阿托品胶浆剂的含量[J].药物分析杂志,2007,27(1):139-140. 被引量:6
  • 3尹东东,王杏林,赵广荣,李萌.依托泊苷微乳的HPLC测定[J].中国医药工业杂志,2007,38(2):121-122. 被引量:16
  • 4吴俊珠,金拓.环孢菌素A安全应用及药动学研究新进展[J].中国药房,2007,18(8):634-637. 被引量:11
  • 5Jiang J, Hu C. Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa[J]. Molecules, 2009,14: 1852-1859.
  • 6Shyr MH, Lin LC, Lin TY, et al. Determination and pharmaco- kinetics of cvodiamine in the plasma and feces of conscious rats [J]. Analytica Chimica Acta, 2006,558 : 16-21.
  • 7Yu YL, Lu Y, Tang X, et al. Formulation, Preparation and E valuation of an Intravenous Emulsion Containing Brueea Javan- ica Oil and Coix Seed Oil for Anti-tumor Application[J]. Biol Pharm Bull,2008,31 (4) :673-680.
  • 8Xu JH, Liu WY, Zheng F,et al. Determination of EVO by high performance liquid chromatography-tandem masss pectrometry and pharmacokinetie studies in rats[J]. Chin J Clin Pharmacol Ther, 2007,12 : 427-433.
  • 9Nanotechnology: Intelligent design to treat complex disease [J]. Pharm Res,2006,23 (7) : 1417-1450.
  • 10Liao C H, Pan S L, Guh J H, et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evod~ae Fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo[ J]. Carcinogenesis, 2005, 26:968-975.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部